These are published, peer-reviewed papers on PRP platelet concentration and on EmCyte PRP kits. Each entry links to the paper, says what it measured, gives one plain line on what it reported, and states who funded it and any author tie to EmCyte, as the paper itself discloses.
NewGen Biologics is an EmCyte distributor. Read the EmCyte entries with that in mind, and read each paper yourself before you rely on it.
How each entry is labeled
Studied an EmCyte kit The paper measured an EmCyte kit.
PRP-class literature The paper is about PRP in general. It did not test any kit NewGen sells, and its results are not results for those kits.
Funding and ties to EmCyte: quoted from the paper's own funding and disclosure statements. Where a statement is not public, the entry says so.
Studies that measured EmCyte kits
Prysak MH, Kyriakides CP, Zukofsky TA, Reutter SE, Cheng J, Lutz GE. PM&R 2021;13:1410-1417. doi:10.1002/pmrj.12569
Studied an EmCyte kit PurePRP II 60 mL.
What it measured: the cell content of 118 PurePRP II 60 mL preparations made for 105 patients during routine care at one private practice, on two protocols.
What it reported: platelet enrichment and the inclusion or exclusion of granulocytes met or exceeded the manufacturer's stated expectations on both protocols; red cell content (hematocrit) was slightly higher than expected on the low red cell protocol; a smaller final volume (4 mL instead of 7 mL) raised the concentration multiple without changing the total platelet count.
Funding and ties to EmCyte: funding listed as the Regenerative SportsCare Foundation. The full disclosure statement is behind the publisher's paywall.
Jildeh TR, Su CA, Vopat ML, Brown JR, Huard J. Cureus 2022;14:e28498. doi:10.7759/cureus.28498
Studied EmCyte kits AbsolutePRP and a PurePRP 60 mL kit, alongside other systems.
What it measured: published specifications, processing time and platelet increase for several point-of-care PRP systems, with a small laboratory test of each (two samples for each EmCyte kit).
What it reported: mean processing time of 13.5 minutes for AbsolutePRP and 18 minutes for the PurePRP 60 mL kit; the authors conclude that differences in how companies report their data make it impossible to recommend a single device.
Funding and ties to EmCyte: the authors declared no competing interests.
PRP-class literature on platelet concentration and dose
Fadadu PP, Mazzola AJ, Hunter CW, Davis TT. Reg Anesth Pain Med 2019;44:652-659. doi:10.1136/rapm-2018-100356
PRP-class literature
What it measured: published preparation and output data for 33 PRP systems and protocols, from 13 studies.
What it reported: only 10 of 33 systems and protocols reached five times the platelets in whole blood, and 3 came out below whole blood. The review also says more is not necessarily better.
Funding and ties to EmCyte: no competing interests declared.
Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. Am J Sports Med 2025;53:745-754. doi:10.1177/03635465241246524
PRP-class literature
What it measured: 18 randomized trials (1,995 patients) of PRP against placebo injections for knee osteoarthritis, with the trials split at 1,000,000 platelets per microliter.
What it reported: in this pooled analysis, the higher-platelet group showed a pain improvement above the threshold patients notice at 3, 6 and 12 months, and the lower-platelet group did not on that pain score.
Funding and ties to EmCyte: the authors declared no conflicts of interest.
Berrigan WA, Bailowitz Z, Park A, Reddy A, Liu R, Lansdown D. Arthroscopy 2025;41:809-817. doi:10.1016/j.arthro.2024.03.018
PRP-class literature
What it measured: the platelet dose given in 29 randomized trials of PRP for knee osteoarthritis, set against whether each trial's PRP group improved at 6 and 12 months.
What it reported: trials with a positive result used a mean dose of about 5.5 billion platelets; the three without one used about 2.3 billion. The authors word it as "may be related".
Funding and ties to EmCyte: the disclosure statement is behind the publisher's paywall.
Bansal H, Leon J, Pont JL, Wilson DA, Bansal A, Agarwal D, Preoteasa I. Sci Rep 2021;11:3971. doi:10.1038/s41598-021-83025-2
PRP-class literature The PRP was made by hand in a laboratory method, not with a commercial kit.
What it measured: 150 patients with knee osteoarthritis given either PRP adjusted to 10 billion platelets or hyaluronic acid, followed for one year.
What it reported: the PRP group had better knee function and pain scores than the hyaluronic acid group at one year.
Funding and ties to EmCyte: funded by Anupam Hospital, Rudrapur, India; the authors declared no competing interests.
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Int J Mol Sci 2020;21:7794. doi:10.3390/ijms21207794
PRP-class literature A review.
What it covers: how PRP preparation and composition (platelet dose, white cells, red cells) relate to its biological activity, from laboratory, animal and human studies.
What it reported: the authors propose that platelet dose and the choice of white and red cell content be set deliberately for each use, and note that laboratory findings often do not carry over to patients.
Funding and ties to EmCyte: the paper states that its first author is Chief Scientific Officer of EmCyte Corporation and Director of Gulf Coast Biologics; no external funding.
NewGen Biologics is an EmCyte distributor. Each entry says what a paper measured and reported. None is a claim that a kit NewGen sells produces these results, and the choice of preparation is the physician's.
Questions about a study? Call (216) 202-4520 or email info@newgenbiologics.com.